Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2017
Price : $35 *
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 May 2017 Status changed from recruiting to completed.
- 08 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.
- 08 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as per ClinicalTrials.gov record.